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Attenuation of inducible, T cell–dependent experimental colitis in 
IRF4-knockout mice. To determine the functional role of IRF4 in 
Figure 1
IRF4 expression is increased in inflammatory bowel diseases. (A) Immunofluorescence staining of human mucosal cryosections for IRF4. 
Cryosections of gut specimens from control patients and IBD patients (n = 10 per group) were stained with antibodies against IRF4 (red). Nuclei 
were counterstained with DAPI (blue). Original magnification, ×300. (B) Quantitative assessment of IRF4-positive cells. IRF4-positive cells were 
counted in 7 HPFs per patient. There was a significantly increased number of IRF4-expressing cells in both CD and UC patients as compared 
with control patients. **P < 0.01. (C) Quantitative assessment of IRF4 and IL-6 mRNA in the lamina propria. IRF4 and IL-6 mRNA levels in muco-
sal biopsies were determined by quantitative PCR. A total of 16 IBD patients were analyzed. Values for IRF4 and IL-6 were strongly correlated 
(r = 0.81) in IBD. (D) Immunofluorescence double staining for IRF4 and CD3. Double-staining analysis was performed (green, IRF4-positive cells; 
red, CD3-positive cells). Original magnification, ×400 (upper panels); ×1000 (lower panels). Cells coexpressing IRF4 and CD3 appeared yellow 
(arrow). Staining analysis revealed that a large number of IRF4-positive cells coexpress CD3 on their surface. (E) Immunofluorescence double 
staining for IRF4 and CD4, CD8, and CD11c. Cells were stained using anti-IRF4 antibodies, and additional surface staining was performed using 
antibodies against either CD11c, CD8, or CD4. The number of positive cells was analyzed in 7 HPFs per patient (n = 6). CD11c, CD8, and CD4 
single-positive cells and the number of double-positive cells were counted. Data represent mean values ± SD.
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Abrogation of oxazolone-induced colitis in IRF4-deficient mice. (A) IRF4 expression was analyzed by immunofluorescence (red) in oxazolone 
colitis. IRF4–/– mice served as negative control (upper panel). Colitic WT mice had many IRF4-positive cells in the lamina propria (lower panel) 
as compared with untreated WT mice (middle panel). Original magnification, ×400. *P < 0.05. (B) WT (n = 8) and IRF4-deficient mice (n = 11) 
were treated by rectal administration of oxazolone following prior sensitization. WT (IRF4+/+) mice lost significantly more weight as compared with 
oxazolone-treated IRF4–/– mice, untreated WT mice (n = 5), or untreated knockout mice (n = 3). **P < 0.01 on days 3 and 4. (C) IRF4-deficient 
mice showed a significantly reduced endoscopic score. (D) Representative endoscopic pictures from each group are shown. (E) Histological 
scoring revealed a significantly higher degree of inflammation in oxazolone-treated WT mice as compared with IRF4–/– mice. Data are given 
as mean values ± SEM (IRF4+/+ plus oxazolone, n = 8; IRF4–/– plus oxazolone, n = 11; IRF4+/+, n = 5; IRF4–/–, n = 3). (F) Histological findings 
showed moderate to severe inflammation in WT mice, whereas little or no inflammation was noted in IRF4–/– mice. (G) In further studies, chronic 
oxazolone colitis was evaluated. Mice were treated 3 times by intrarectal application of oxazolone and evaluated on day 21. A more severe colitis 
activity was induced in WT mice (n = 5) as compared with IRF4–/– mice (n = 5) (F). This was underlined by differences (**P < 0.01) in the histologic 
score between both groups (G). (H) Representative histologic pictures from each group are shown. Original magnification, ×100.
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Attenuation of TNBS-induced colitis in IRF4-deficient mice. (A) IRF4-deficient mice and WT control mice were treated by intrarectal administra-
tion of the hapten reagent TNBS followed by monitoring of body weight. TNBS-treated IRF4–/– mice lost significantly (P < 0.05) less weight as 
compared with WT mice. One representative experiment out of 3 is shown. Endoscopic (B and C) and histologic (D and E) analyses showed 
significantly reduced inflammation in TNBS-treated IRF4–/– mice as compared with TNBS-treated WT mice. *P < 0.05; **P < 0.01. Data are 
given as mean values ± SEM (IRF4+/+ plus TNBS, n = 17; IRF4–/– plus TNBS, n = 14; IRF4+/+, n = 8; IRF4–/–, n = 11). Data were pooled from 3 
independent experiments. Original magnification, ×100.
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Differences in mucosal IL-6 expression 
between WT and IRF4-deficient mice. On 
day 4, colons of the different groups of mice 
were analyzed for cytokine levels by quantita-
tive PCR. Relative expression levels of IL-6, 
TNF, TGF-β, IFN-γ, and IL-13 mRNA were 
measured by quantitative real-time RT-PCR. 
Values were normalized to β-actin expres-
sion levels. (A) The mRNA expression of 
various pro- and antiinflammatory cytokines 
in the colons of oxazolone-treated IRF4-defi-
cient and WT mice was analyzed by quan-
titative PCR (n = 8 per group). Whereas no 
differences were noted in the expression of 
TGF-β and TNF, IL-6 mRNA expression was 
strongly induced in WT but not IRF4-deficient 
mice upon oxazolone administration. In addi-
tion, there were no significant differences 
in IL-13 mRNA levels between the groups. 
**P < 0.01. (B) The mRNA expression pat-
tern of several cytokines was also deter-
mined in TNBS colitis (n = 8 per group). 
Whereas no significant differences in the 
expression of the proinflammatory cytokines 
TNF and IFN-γ were noted between the 
groups, IL-6 mRNA expression was strongly 
induced in WT but not IRF4-deficient mice 
upon TNBS administration. *P < 0.05.
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Decreased activation of the antiapoptotic IL-6 pathway in IRF4-deficient T cells. (A) LPMCs from WT and IRF4-deficient mice were cultured with 
or without anti-CD3/CD28 antibodies. IL-6 production was higher in WT mice as compared with IRF4-deficient mice upon costimulation. (B–D) T 
cell–enriched LPMCs (B), CD90+ LP T cells (C), or splenic T cells (D) were isolated from TNBS-treated mice and stimulated for 2 days. LP cells 
but not spleen cells from TNBS-treated IRF4-deficient mice produced significantly lower amounts of IL-6 than cells from TNBS-treated WT mice 
(n = 9–10 mice per group; **P < 0.01) (E) TNBS-treated WT mice exhibited an increased number of IL-6–positive cells (red) in the lamina propria 
as compared with controls. Original magnification, ×300. (F) IL-6–positive cells were counted in TNBS-treated IRF4–/– and WT mice (5 HPFs). 
IL-6–positive cells were increased in TNBS-treated WT mice compared with IRF4-deficient mice. (G) Colonic cryosections were stained using 
TUNEL assays. There were more positive cells in the colons of TNBS-treated IRF4-knockout mice than in TNBS-treated WT mice (n = 6 per 
group). Positive and negative control samples are shown. Original magnification, ×300. (H) Lamina propria cells were isolated from either TNBS-
treated WT or IRF4–/– mice (n = 6 per group) and stained for CD3 and annexin V. Lamina propria cells from IRF4–/– mice showed more annexin V 
and CD3 double-positive cells than those from WT mice (15% versus 3%). No such differences were detected in spleen cells (8% versus 11%).
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The protective effect of IRF4 deficiency is abrogated in TNBS and 
oxazolone colitis by administration of recombinant IL-6 or hyper–IL-6. 
(A) To determine the functional role of IL-6 signaling for the effects of 
IRF4 on TNBS colitis activity in vivo, recombinant IL-6 or the designer 
fusion protein hyper–IL-6 was intraperitoneally administered to TNBS-
treated IRF4-deficient mice. TNBS-treated IRF4–/– mice exhibited 
severe inflammation and weight loss upon IL-6 or hyper–IL-6 treat-
ment that was indistinguishable from colitis in WT control mice (TNBS-
treated IRF4–/– plus hyper–IL-6 versus TNBS-treated IRF4–/– without 
hyper–IL-6; *P < 0.05). Data are given as mean values ± SEM (IRF4+/+ 
plus TNBS, n = 6; IRF4–/– plus TNBS, n = 7; IRF4–/– plus TNBS and 
hyper–IL-6, n = 5; IRF4–/– plus TNBS and hyper–IL-6, n = 5; IRF4+/+ 
plus TNBS and IL-6, n = 4; IRF4–/– plus TNBS and hyper–IL-6, n = 5, 
in 2 independent experiments). (B) To determine the functional role 
of IL-6 signaling for the effects of IRF4 on oxazolone colitis activity 
in vivo, hyper–IL-6 was intraperitoneally administered to oxazolone-
treated IRF4-deficient mice. Oxazolone-treated IRF4–/– mice exhibited 
severe inflammation and weight loss upon hyper–IL-6 treatment that 
was indistinguishable from colitis in WT control mice (oxazolone-treat-
ed IRF4–/– plus hIL6 versus oxazolone-treated IRF4–/– without hIL6). 
Data are given as mean values ± SEM (IRF4+/+ plus oxazolone [oxa], 
n = 12; IRF4–/– plus oxazolone, n = 13; IRF4–/– plus oxazolone plus 
hyper–IL-6, n = 7; IRF4+/+ plus oxazolone plus hyper–IL-6, n = 6, in 3 
independent experiments).
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Hyper–IL-6 treatment induces IL-6 but not TNF production in IRF4–/– mice. (A) WT and IRF4-knockout mice were treated with TNBS, and some 
mice received hyper–IL-6. Relative expression levels of IL-6, TNF, and TGF-β mRNA were measured by quantitative real-time RT-PCR on 
day 4. Values were normalized to β-actin expression levels. TNBS-treated IRF4–/– mice (n = 8) showed low mucosal expression of IL-6 mRNA. 
Hyper–IL-6 application induced a 14-fold increase of IL-6 production in TNBS-treated IRF4–/– mice (n = 6) (**P < 0.01). The expression levels of 
the proinflammatory cytokine TNF as well as levels of TGF-β remained unaffected, however. Treatment of WT mice with hyper–IL-6 (n = 5; WT 
mice, n = 4) did not lead to a further significant increase of IL-6, TNF, or TGF-β. Data are shown as mean values ± SEM from 3 experiments. 
(B and C) IRF4-knockout mice and WT mice were treated with TNBS, and the presence of apoptosis in gut mononuclear cells was determined 
by propidium iodide and annexin V staining using FACS analysis (n = 6 per group). IRF4-deficient mononuclear cells in the gut showed a sig-
nificantly higher presence of cell apoptosis in TNBS colitis than in WT cells, and this could be abrogated by hyper–IL-6 administration. One 
representative experiment is shown. *P < 0.05. (D) Apoptosis of gut mononuclear cells was determined by TUNEL assays. Hyper–IL-6 treatment 
prevented the induction of mononuclear cell apoptosis in the colon of IRF4-deficient mice. One representative experiment is shown (n = 4 per 
group). Original magnification, ×300.
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The protective effects of IRF4 deficiency are mediated via T lymphocytes: studies in the CD45RBhi adoptive transfer model of colitis. 
CD45RBhiCD4+ T cells from WT or IRF4–/– mice were adoptively transferred into immunodeficient RAG2–/– mice. Whereas RAG2–/– mice recon-
stituted with WT T cells developed severe colitis accompanied by weight loss (A, red curve), mice given IRF4–/– T cells were completely protected 
and even gained body weight (A, blue curve). One representative experiment out of 3 with 4 to 7 mice per group is shown. The differences 
between both groups were significant at days 14 and 15. (B) Endoscopy showed an inflamed mucosa in RAG2-knockout mice given WT T cells, 
whereas little or no inflammation was noted in RAG2–/– mice reconstituted with IRF4-deficient T cells. (C) Consistently, histological scoring (n = 8 
per group) revealed significantly reduced colitis activity in the latter as compared with the former group of mice (**P < 0.01). Whereas the WT 
group showed marked inflammation, only a very mild colitis was noted in the IRF4-deficient group. (D) For each group, representative endoscopic 
and histologic pictures are shown. Original magnification, ×100.
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Analysis of cytokine expression and apoptosis in the colon of reconstituted mice. (A) Expression of cytokine mRNA levels in the colon of RAG2-
knockout mice reconstituted with WT or IRF4-deficient T cells was performed by quantitative PCR. Whereas mucosal IL-6 expression was sig-
nificantly higher (**P < 0.01) in RAG2-knockout mice reconstituted with WT but not IRF4-deficient cells, no significant differences were noted in 
TNF and TGF-β levels. One representative experiment out of 3 is shown. (B) In addition, TUNEL assays on colonic cryosections were performed 
to detect apoptotic LPMCs. There was a significantly higher number of apoptotic LPMCs in the colons of mice reconstituted with IRF4-deficient 
T cells as compared with mice given WT T cells. Original magnification, ×200.
Downloaded from http://www.jci.org on July 22, 2015.   http://dx.doi.org/10.1172/JCI33227
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 118      Number 7      July 2008  2425





































































tored. The  level of  cytokine mRNA relative  to actin was  calculated 
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